In particular, the combining of two separate drugs such as the FLT3 inhibitor, Quizartinib and the Bcl-2 inhibitor Venetoclax which have demonstrated synergistic cell death in AML, could be partially attributed to the increases in ceramide levels that are produced by each drug39,67,97. The gene discussed is BCL2; the disease is acute myeloid leukemia.